Tarsus CMO Jose Trevejo departs; clinical dev reorganizes under COO

Tarsus Pharmaceuticals, Inc.

Dr. Trevejo steps down as CMO effective Jan 18, 2024; employment ends Feb 17, 2024.
Clinical development and medical affairs reorganized under COO Dr. Sesha Neervannan.
Transition approved Jan 11, 2024; company expresses gratitude for Dr. Trevejo's service.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jose Trevejo

Chief Medical Officer

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2024-01-18
Filed: January 18, 2024, 6:59 PM ET

On January 18, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Jose Trevejo, M.D., Ph.D. would be leaving his role as the Company’s Chief Medical Officer (the “Transition”), effective as of January 18, 2024 (the “Transition Date”), and leaving his employment with the Company on February 17, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jose Trevejo departed as Chief Medical Officer at Tarsus Pharmaceuticals, Inc..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

On January 18, 2024, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Jose Trevejo, M.D., Ph.D. would be leaving his role as the Company’s Chief Medical Officer (the “Transition”), effective as of January 18, 2024 (the “Transition Date”), and leaving his employment with the Company on February 17, 2024.

View on SEC.gov

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.